These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 16292330

  • 1. PET network abnormalities and cognitive decline in patients with mild cognitive impairment.
    Devanand DP, Habeck CG, Tabert MH, Scarmeas N, Pelton GH, Moeller JR, Mensh BD, Tarabula T, Van Heertum RL, Stern Y.
    Neuropsychopharmacology; 2006 Jun; 31(6):1327-34. PubMed ID: 16292330
    [Abstract] [Full Text] [Related]

  • 2. Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance.
    Scarmeas N, Habeck CG, Zarahn E, Anderson KE, Park A, Hilton J, Pelton GH, Tabert MH, Honig LS, Moeller JR, Devanand DP, Stern Y.
    Neuroimage; 2004 Sep; 23(1):35-45. PubMed ID: 15325350
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.
    Devanand DP, Pelton GH, Zamora D, Liu X, Tabert MH, Goodkind M, Scarmeas N, Braun I, Stern Y, Mayeux R.
    Arch Neurol; 2005 Jun; 62(6):975-80. PubMed ID: 15956169
    [Abstract] [Full Text] [Related]

  • 5. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment.
    Chételat G, Eustache F, Viader F, De La Sayette V, Pélerin A, Mézenge F, Hannequin D, Dupuy B, Baron JC, Desgranges B.
    Neurocase; 2005 Feb; 11(1):14-25. PubMed ID: 15804920
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA, Pua EP, Zhou J, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2015 Feb; 45(1):253-68. PubMed ID: 25524955
    [Abstract] [Full Text] [Related]

  • 9. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study.
    Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A.
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1104-13. PubMed ID: 12764551
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. MCI patients declining and not-declining at mid-term follow-up: FDG-PET findings.
    Pagani M, Dessi B, Morbelli S, Brugnolo A, Salmaso D, Piccini A, Mazzei D, Villavecchia G, Larsson SA, Rodriguez G, Nobili F.
    Curr Alzheimer Res; 2010 Jun; 7(4):287-94. PubMed ID: 19939228
    [Abstract] [Full Text] [Related]

  • 12. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.
    Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MT, Padovani A, Borroni B, Franceschi M, Bracco L, Pupi A.
    Neurology; 2004 Dec 28; 63(12):2332-40. PubMed ID: 15623696
    [Abstract] [Full Text] [Related]

  • 13. Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment.
    Bokde AL, Lopez-Bayo P, Meindl T, Pechler S, Born C, Faltraco F, Teipel SJ, Möller HJ, Hampel H.
    Brain; 2006 May 28; 129(Pt 5):1113-24. PubMed ID: 16520329
    [Abstract] [Full Text] [Related]

  • 14. FMRI of working memory in patients with mild cognitive impairment and probable Alzheimer's disease.
    Yetkin FZ, Rosenberg RN, Weiner MF, Purdy PD, Cullum CM.
    Eur Radiol; 2006 Jan 28; 16(1):193-206. PubMed ID: 16402259
    [Abstract] [Full Text] [Related]

  • 15. Effects of a 6-month cognitive intervention program on brain metabolism in amnestic mild cognitive impairment and mild Alzheimer's disease.
    Förster S, Buschert VC, Buchholz HG, Teipel SJ, Friese U, Zach C, la Fougere C, Rominger A, Drzezga A, Hampel H, Bartenstein P, Buerger K.
    J Alzheimers Dis; 2011 Jan 28; 25(4):695-706. PubMed ID: 21498904
    [Abstract] [Full Text] [Related]

  • 16. Subcortical vascular versus amnestic mild cognitive impairment: comparison of cerebral glucose metabolism.
    Seo SW, Cho SS, Park A, Chin J, Na DL.
    J Neuroimaging; 2009 Jul 28; 19(3):213-9. PubMed ID: 19021838
    [Abstract] [Full Text] [Related]

  • 17. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease.
    Waragai M, Okamura N, Furukawa K, Tashiro M, Furumoto S, Funaki Y, Kato M, Iwata R, Yanai K, Kudo Y, Arai H.
    J Neurol Sci; 2009 Oct 15; 285(1-2):100-8. PubMed ID: 19552926
    [Abstract] [Full Text] [Related]

  • 18. Different cognitive profiles between mild cognitive impairment due to cerebral small vessel disease and mild cognitive impairment of Alzheimer's disease origin.
    Zhou A, Jia J.
    J Int Neuropsychol Soc; 2009 Nov 15; 15(6):898-905. PubMed ID: 19891819
    [Abstract] [Full Text] [Related]

  • 19. Meta-analytic comparison between PIB-PET and FDG-PET results in Alzheimer's disease and MCI.
    He W, Liu D, Radua J, Li G, Han B, Sun Z.
    Cell Biochem Biophys; 2015 Jan 15; 71(1):17-26. PubMed ID: 25370296
    [Abstract] [Full Text] [Related]

  • 20. FDG-PET mapping the brain substrates of visuo-constructive processing in Alzheimer's disease.
    Förster S, Teipel S, Zach C, Rominger A, Cumming P, Fougere Cl, Yakushev I, Haslbeck M, Hampel H, Bartenstein P, Bürger K.
    J Psychiatr Res; 2010 May 15; 44(7):462-9. PubMed ID: 19875130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.